UroGen Pharma (URGN) Misses Q4 EPS by 6c

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.84 million versus the consensus estimate of $41.45 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Abu Dhabi's G42 Weighs US Ownership To Safeguard AI Chip Access - Bloomberg
• Asana shares tumble on weak third quarter earnings outlook
• StoneX on Mama’s Creations (MAMA): 'We Remain High-Conviction Buyers'